manlius
Forumer attivo
io ho il primo che comunque ha strikes e barriera ben protettivi, ma penso sia meglio il secondo che a fine anno comunque scade.
Ultima modifica:
Certificati di investimento - Cap. 4
- Creatore Discussione percefal
- Data di Inizio
- Stato
Fabrib
Forumer storico
For Biogen Inc., the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called “the mother of all binary events” -- one that could send its shares veering sharply in either direction.
If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much as $450, up from its $272.55 close on Thursday, according to Wall Street analysts. Or it could tumble to $200 if the treatment is shot down, according to Cory Kasimov, the JPMorgan analyst who follows the company.
The forecasts reflect how heavily Biogen’s outlook is tied to the drug, the first that’s thought to slow the progression of the disease in people who show early signs of cognitive impairment. That’s left Wall Street analysts and investors trying to weigh whether regulators will hasten its approval despite mixed reviews that whipsawed the company’s stock late last year.
“The data package is insufficient, and with almost any other indication, we suspect regulators would be asking for another confirmatory trial pre-approval,” Kasimov wrote in a note to clients.
“But this isn’t any other indication. It’s Alzheimer’s. And the unmet need is rather unprecedented,” he wrote. “It’s anyone’s guess as to what happens next.”
Read more: Biogen’s New Alzheimer’s Drug Faces Hurdles Reaching Patients, Even if It’s Approved
Biogen’s stock has traded sideways since November, when it surged on an FDA staff report that said aducanumab appears effective, only to then tumble when an outside panel of agency advisers said the data from a single trial wasn’t sufficient. But activity in bullish Biogen calls has picked up recently, suggesting the market is positioning ahead of the June 7 decision date. BBG
If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much as $450, up from its $272.55 close on Thursday, according to Wall Street analysts. Or it could tumble to $200 if the treatment is shot down, according to Cory Kasimov, the JPMorgan analyst who follows the company.
The forecasts reflect how heavily Biogen’s outlook is tied to the drug, the first that’s thought to slow the progression of the disease in people who show early signs of cognitive impairment. That’s left Wall Street analysts and investors trying to weigh whether regulators will hasten its approval despite mixed reviews that whipsawed the company’s stock late last year.
“The data package is insufficient, and with almost any other indication, we suspect regulators would be asking for another confirmatory trial pre-approval,” Kasimov wrote in a note to clients.
“But this isn’t any other indication. It’s Alzheimer’s. And the unmet need is rather unprecedented,” he wrote. “It’s anyone’s guess as to what happens next.”
Read more: Biogen’s New Alzheimer’s Drug Faces Hurdles Reaching Patients, Even if It’s Approved
Biogen’s stock has traded sideways since November, when it surged on an FDA staff report that said aducanumab appears effective, only to then tumble when an outside panel of agency advisers said the data from a single trial wasn’t sufficient. But activity in bullish Biogen calls has picked up recently, suggesting the market is positioning ahead of the June 7 decision date. BBG
CarloConti
Forumer storico
CH0516983589 sell. Operazione complessivamente decisamente positiva. Comprato l'8/1/2021 a 830 e rivenduto a 900,90, e incassato 100 euro di cedole a certificato. Un 20% in 5 mesi. Essendo venerdì voglio guardare solo le cose positive.......
Ultima modifica:
BRUNO66
Forumer storico
Se resistevi (e quindi non vendevi) potevano, tra un paio di settimane, trasformarsi in 4 cene da ristorante stellato!
valgri
Valter : Born in 1965
Ottimo post , grazie , serve per dare un senso al buon rialzo di oggi..
Ultima modifica:
Fabrib
Forumer storico
Global ratings agency Fitch on Friday affirmed Italy's credit rating at "BBB-", just a notch above junk, saying the COVID-19 pandemic continues to exert an adverse impact on euro zone's third largest economy.
"Very high government debt and structurally weak economic growth weigh on the rating," Fitch said in a statement.
The agency said an expansion of vaccinations, a decline in new coronavirus cases and the re-opening of a vast majority of the country's economy last month would pave the way for a "swift rebound" in economic activity in the second half of this year.
However, Fitch warned a potential emergence of vaccine-resistant variants of the coronavirus is a short-term risk to the country's recovery.
It maintained Italy's outlook at stable.
"Very high government debt and structurally weak economic growth weigh on the rating," Fitch said in a statement.
The agency said an expansion of vaccinations, a decline in new coronavirus cases and the re-opening of a vast majority of the country's economy last month would pave the way for a "swift rebound" in economic activity in the second half of this year.
However, Fitch warned a potential emergence of vaccine-resistant variants of the coronavirus is a short-term risk to the country's recovery.
It maintained Italy's outlook at stable.
- Stato
Similar threads
